Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC
Provided By GlobeNewswire
Last update: May 1, 2025
As SVP, Neuroscience, Dr. Bordey will lead Cassava’s ongoing research and development efforts
Dr. Bordey to direct the scientific evaluation of simufilam in TSC-related epilepsy, and potentially additional pipeline indications
Read more at globenewswire.comNASDAQ:SAVA (11/17/2025, 1:55:41 PM)
2.8
+0.04 (+1.45%)
Find more stocks in the Stock Screener
